98665-16-8
Chemical Structure
Lucidenic acid D
Synonym(s): Lucidenic acid D2
- CAS No.: 98665-16-8
- Formula:C29H38O8
- Molecular Weight:514.61
IUPAC Name: (R)-4-((5R,10S,12S,13R,14R,17R)-12-acetoxy-4,4,10,13,14-pentamethyl-3,7,11,15-tetraoxo-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
InChIKey: LTJSBYAKDOGXLX-JTJCPSTFSA-N
SMILES: C[C@@]([C@@H]1OC(C)=O)([C@@](C2)([H])[C@H](C)CCC(O)=O)[C@](C(C(C[C@@]3([H])C4(C)C)=O)=C([C@]3(CCC4=O)C)C1=O)(C2=O)C
Biological Activity: Lucidenic acid D is a highly oxidized triterpenoid with anti-inflammatory and antiviral activities. Lucidenic acid D attenuates lipopolysaccharide-induced release of proinflammatory cytokines and nitric oxide, reduces the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits skin inflammation. Lucidenic acid D suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of Epstein-Barr virus (EBV) early antigen and maintains the viability of Raji cells. Lucidenic acid D can be used in studies of cancer chemoprevention[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lucidenic acid D | 99.41% | Lucidenic acid D is a highly oxidized triterpenoid with anti-inflammatory and antiviral activities. Lucidenic acid D attenuates lipopolysaccharide-induced release of proinflammatory cytokines and nitric oxide, reduces the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and inhibits skin inflammation. Lucidenic acid D suppresses 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced expression of Epstein-Barr virus (EBV) early antigen and maintains the viability of Raji cells. Lucidenic acid D can be used in studies of cancer chemoprevention. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Tohru Kikuchi, et al. GANODERIC ACID D, E, F, AND H AND LUCIDENIC ACID D, E, AND F, NEW TRITERPENOIDS FROM GANODERMA LUCIDUM. Chem Pharm Bull. 1985, 33 (6): 2624-2627.
- [2]. Zheng C, et al. A Review on the Sources, Structures, and Pharmacological Activities of Lucidenic Acids. Molecules. 2023;28(4):1756. Published 2023 Feb 12. [Content Brief]
- [3]. Watanabe K, et al. Lucidenic acids-rich extract from antlered form of Ganoderma lucidum enhances TNFα induction in THP-1 monocytic cells possibly via its modulation of MAP kinases p38 and JNK. Biochem Biophys Res Commun. 2011;408(1):18-24. [Content Brief]
- [4]. Iwatsuki K, et al. Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation. J Nat Prod. 2003;66(12):1582-1585. [Content Brief]
Keywords
